References
- BlueRock Therapeutics . BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies(2023). www.bluerocktx.com/bluerock-therapeutics-and-bit-bio-announce-collaboration-and-option-agreement-for-the-discovery-and-manufacture-of-regulatory-t-cell-treg-based-therapies/
- CARsgen Therapeutics . CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine(2023). www.carsgen.com/en/news/2023-08-21/
- CytoMed Therapeutics . CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency(2023). https://investor.cytomed.sg/news-and-events/news/news-details/2023/CytoMed-Therapeutics-Announces-China-Research-Collaboration-to-Enhance-its-Allogeneic-CAR--T-In-Vivo-Persistency/default.aspx
- XNK Therapeutics . XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)(2023). https://xnktherapeutics.com/en/xnk-therapeutics-enters-into-research-collaboration-with-karolinska-university-hospital-in-acute-myeloid-leukemia-aml/
- Cellares . Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform(2023). www.cellares.com/news/cellares-announces-bristol-myers-squibb-has-joined-technology-adoption-partnership-program-to-evaluate-automated-manufacturing-of-car-t-cell-therapy-on-the-cell-shuttle-platform/
- PR Newswire . GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA(2023). www.prnewswire.com/news-releases/genscript-biotech-and-t-maximum-biotech-form-strategic-alliance-on-cgmp-sgrna-301897032.html
- BlueRock Therapeutics . BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint(2023). www.bluerocktx.com/bluerocks-phase-i-study-with-bemdaneprocel-in-patients-with-parkinsons-disease-meets-primary-endpoint/
- NCT04802733 . Phase I Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease(2023). www.clinicaltrials.gov/study/NCT04802733
- NCT05897957 . Continued Evaluation of Patients with Parkinson's Disease Who Previously Received BRT-DA01(2023). www.clinicaltrials.gov/study/NCT05897957
- Anixa Biosciences . Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial(2023). https://ir.anixa.com/press-releases/detail/1021/anixa-biosciences-announces-treatment-of-third-patient-in
- NCT05316129 . Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer(2023). www.clinicaltrials.gov/study/NCT05316129
- CARsgen Therapeutics . CARsgen Initiates Phase II Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S(2023). www.carsgen.com/en/news/2023-05-18/
- NCT04400383 . Clinical Trial to Evaluate AB011 Injection in Patients with CLDN18.2-positive Advanced Solid Tumors(2023). www.clinicaltrials.gov/study/NCT04400383
- PR Newswire. Aegle Therapeutics Corp . Announces First Patient Dosed in Phase I/IIa Clinical Trial Administering a Novel Extracellular Vesicle Therapy(2023). www.prnewswire.com/news-releases/aegle-therapeutics-corp-announces-first-patient-dosed-in-phase-12a-clinical-trial-administering-a-novel-extracellular-vesicle-therapy-301901638.html
- NCT05078385 . Safety of Extracellular Vesicles for Burn Wounds(2023). http://www.clinicaltrials.gov/study/NCT05078385
- Arcellx . Arcellx Announces Partial Clinical Hold Lifted On IMMagine-1 Phase II Clinical Program And Reports Second Quarter Financial Results(2023). https://ir.arcellx.com/news/news-details/2023/Arcellx-Announces-Partial-Clinical-Hold-Lifted-on-iMMagine-1-Phase-2-Clinical-Program-and-Reports-Second-Quarter-Financial-Results/default.aspx
- NCT05396885 . Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)(2023). https://classic.clinicaltrials.gov/ct2/show/NCT05396885
- Aspen Neuroscience . Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson's Disease(2023). https://aspenneuroscience.com/aspen-neuroscience-announces-fda-clearance-of-investigational-new-drug-application-for-anpd001-autologous-cell-therapy-for-the-treatment-of-parkinsons-disease/
- ImmPACT Bio USA . Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus(2023). https://immpact-bio.com/news-and-events/immpact-bio-announces-fda-clearance-of-ind-application-for-bispecific-cd19-cd20-car-t-therapy-impt-514-for-the-treatment-of-refractory-systemic-lupus-erythematosus/
- PR Newswire . Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency(2023). www.prnewswire.com/news-releases/approval-of-an-orphan-disease-application-for-its-lead-product-the-cellspan-esophageal-implant-by-the-european-medicines-agency-301905136.html
- Kerecis . New Kerecis Medical-Fish-Skin Product Gets Quick Approval from Medicare Administrative Contractors(2023). www.kerecis.com/new-kerecis-product-gets-quick-approval-from-medicare-administrative-contractors/
- Nexcella . U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma(2023). https://nexcella.com/2023/08/23/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-nxc-201-as-a-treatment-for-multiple-myeloma/
- Nexcella . NXC-201 (Formerly HBI0101) Multiple Myeloma(2023). www.clinicaltrials.gov/study/NCT04720313
- Oricell Therapeutics . Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact(2023). www.oricell.com/en/about/news/192.html
- Mesoblast . Mesoblast Receives Complete Response from U.S. Food and Drug Administration For Biologics License Application For Steroid-Refractory Acute Graft Versus Host Disease In Children(2023). https://investorsmedia.mesoblast.com/static-files/422cd6da-a0b9-49cf-a177-7fd106f111f2
- Cellares . Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies(2023). www.cellares.com/news/cellares-raises-255m-series-c-to-launch-first-integrated-development-and-manufacturing-organization-idmo-and-pioneering-smart-factory-to-meet-global-demand-for-life-saving-cell-therapies/
- Gracell Biotechnologies . Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors(2023). https://ir.gracellbio.com/node/8681/pdf
- Kyverna Therapeutics . Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors(2023). https://kyvernatx.com/press-releases/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors/
- Park A . Neuralink nabs $280M after scoring FDA OK to begin human trials of brain implant. Fierce Biotech (2023). www.fiercebiotech.com/medtech/neuralink-nabs-280m-after-scoring-fda-ok-begin-human-trials-brain-implant
- Poseida Therapeutics . Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy(2023). https://investors.poseida.com/node/8536/pdf